Virbac, maker of Stelfonta, the intratumoural solution to treat mast cell tumours in dogs, is hosting a livestream interactive talk with guest speaker Dr Gerry Polton (RCVS & European Specialist in Veterinary Oncology) on 17th May at 8:00pm.

Virbac points to research showing that MCTs are the most common form of skin cancer in dogs, accounting for up to 21% of skin cancer cases1.

This, says the company, means that understanding the challenges surrounding mast cell tumour diagnosis, work up (including the various prognostic panels) and treatment selection for mast cell tumour cases is vital.

The session, entitled ‘Fundamentals of Mast Cell Tumour Management’, will conclude with a review of Stelfonta, walking through cases and how to get the best results. 

Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "We know that vets are facing webinar fatigue.

"We therefore hope that this brand new style of online learning on one of the most common canine cancers will be more engaging, whilst still delivering high quality CPD."

To register for the live event, visit:

For more information, speak to your Virbac Territory Manager, or visit


  1. Garrett, L.D. (2014) Canine mast cell tumors: diagnosis, treatment, and prognosis. Veterinary Medicine: Research and Reports, Vol 5.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.